Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $59.12, for a total value of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares of the company’s stock, valued at approximately $15,812,412.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total value of $374,972.90.
• On Wednesday, September 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $47.56, for a total value of $316,987.40.

Apogee Therapeutics Price Performance

Shares of APGE opened at $61.12 on Friday. The business has a 50-day moving average of $54.25 and a 200-day moving average of $48.78. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -29.53 and a beta of 2.93. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in Apogee Therapeutics during the 3rd quarter worth about $300,000. Jennison Associates LLC boosted its position in shares of Apogee Therapeutics by 2.1% during the 3rd quarter. Jennison Associates LLC now owns 312,611 shares of the company’s stock valued at $18,363,000 after purchasing an additional 6,533 shares in the last quarter. Natixis Advisors LLC acquired a new stake in Apogee Therapeutics during the third quarter worth approximately $879,000. Victory Capital Management Inc. grew its stake in Apogee Therapeutics by 121.6% during the third quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock worth $20,345,000 after purchasing an additional 190,092 shares during the period. Finally, AlphaCentric Advisors LLC bought a new stake in Apogee Therapeutics in the third quarter worth approximately $499,000. Institutional investors own 79.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an “outperform” rating and set a $87.00 target price on shares of Apogee Therapeutics in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $78.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.